SCHEMBL3429617

SCHEMBL3429617

CCNCCCCc1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 12/20 0.73
L3MBTL1 Q9Y468 1/20 0.64
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10649922 0.98 SIGMAR1 (0.77) SIGMAR1L3MBTL1MEN1KMT2A
SCHEMBL22251830 0.98 SIGMAR1 (0.77) SIGMAR1L3MBTL1MEN1KMT2A
SCHEMBL9324795 0.98 SIGMAR1 (0.77) SIGMAR1L3MBTL1MEN1KMT2A
SCHEMBL3441609 0.94 SIGMAR1 (0.75) SIGMAR1MEN1KMT2A
Iodide SCHEMBL31425558 0.92 SIGMAR1 (0.72) SIGMAR1MEN1KMT2A
SCHEMBL4344582 0.92 SIGMAR1 (0.72) SIGMAR1MEN1KMT2A
Hydrochloric Acid SCHEMBL8508325 0.92 SIGMAR1 (0.72) SIGMAR1MEN1KMT2A
Sulfuric Acid SCHEMBL10335410 0.91 MEN1 (0.63) SIGMAR1L3MBTL1MEN1KMT2A
SCHEMBL11699466 0.89 SIGMAR1 (0.58) SIGMAR1L3MBTL1
SCHEMBL7165896 0.88 TAAR1 (0.61) SIGMAR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210292353-A1 INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-09-23 US claimed
CN-1343024-A Organic amine used as additive in electrochemical battery MERCK PATENT GMBH (DE) 2002-04-03 CN claimed
EP-1187244-A2 Organic amines as additives for electrochemical cells MERCK PATENT GmbH (DE) 2002-03-13 EP claimed
US-20100323098-A1 ELECTRODE MATERIAL FOR RECHARGEABLE LITHIUM BATTERY, ELECTRODE STRUCTURAL BODY COMPRISING SAID ELECTRODE MATERIAL, RECHARGEABLE LITHIUM BATTERY HAVING SAID ELECTRODE STRUCTURAL BODY, PROCESS FOR THE PRODUCTION OF SAID ELECTRODE STRUCTURAL BODY, AND PROCESS FOR THE PRODUCTION OF SAID RECHARGEABLE LITHIUM BATTERY CANON KABUSHIKI KAISHA (JP) 2010-12-23 US disclosed
US-7803290-B2 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2010-09-28 US disclosed
US-7566734-B2 Imidazolyl derivatives SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2009-07-28 US disclosed
US-7504391-B2 Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders SCHERING CORPORATION (US) 2009-03-17 US disclosed
WO-2008149053-A1 BICYCL0 [2. 2. 1] HE PT- 2-YLAMINE DERIVATES AND THEIR USE ARGENTA DISCOVERY LTD. (GB) 2008-12-11 WO disclosed
US-20080090152-A1 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structual body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2008-04-17 US disclosed
US-7316792-B2 Electrode material for rechargeable lithium battery and electrode structural body comprising said electrode material CANON KABUSHIKI KAISHA (JP) 2008-01-08 US disclosed
WO-2007054971-A2 USE OF ACID SCAVENGERS IN REMOVAL OF PROTONS (ACIDITY) OF THE REACTION MASS DURING CHLORINATION OF SUCROSE-6- ACETATE PHARMED MEDICARE PVT. LTD. (IN) 2007-05-18 WO disclosed
US-20070032653-A1 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2007-02-08 US disclosed
US-7141187-B2 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2006-11-28 US disclosed
US-20060237697-A1 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2006-10-26 US disclosed
US-20030157407-A1 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2003-08-21 US disclosed
CN-1343024-A Organic amine used as additive in electrochemical battery MERCK PATENT GMBH (DE) 2002-04-03 CN disclosed
EP-1187244-A2 Organic amines as additives for electrochemical cells MERCK PATENT GmbH (DE) 2002-03-13 EP disclosed
US-4987132-A PLATELET ACTIVATING FACTOR ANTAGONISTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1991-01-22 US disclosed
EP-0279681-A2 Saturated heterocyclic carboxamide derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1988-08-24 EP disclosed
EP-0002604-A1 Quaternary ammonium salts, and their formulations and preparation ELI LILLY AND COMPANY (US) 1979-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032653-A1 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. GHSR, IGF1R, GIPR SIGMAR1 505/4885L3MBTL1 2514/4885MEN1 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.